
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular, or as to the action to be taken, you should consult your stockbroker or other licensed securities dealer, bank manager, solicitor, professional accountant or other professional advisers.

If you have sold or transferred all your shares in **LongBio Pharma (Suzhou) Co., Ltd.**, you should at once hand this circular, together with the form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



LongBio Pharma (Suzhou) Co., Ltd.
天辰生物醫藥（蘇州）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1779)

**PROPOSED APPOINTMENT OF A NON-EXECUTIVE DIRECTOR
AND
NOTICE OF EXTRAORDINARY GENERAL MEETING**

A notice convening the EGM of LongBio Pharma (Suzhou) Co., Ltd. to be held at Room 302, Building 88, No. 887 Zuchongzhi Road, Zhangjiang High-Tech Park, Pudong New District, Shanghai, PRC on Thursday, September 10, 2026 at 4:00 p.m. is set out on pages 7 to 8 of this circular. A form of proxy for use at the EGM is enclosed. The form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.longbio.com).

Whether or not you are able to attend the EGM, you are requested to complete and sign the accompanying form of proxy in accordance with the instructions printed thereon and return it to the Company's H share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, as soon as possible but in any event not later than 24 hours before the time appointed for holding the EGM or any adjournment thereof (i.e. by 4:00 p.m. on Wednesday, September 9, 2026). Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM if you so wish. If you attend and vote in person at the EGM, your form of proxy will be revoked.

August 21, 2026

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
NOTICE OF EXTRAORDINARY GENERAL MEETING	7

DEFINITIONS

In this circular, unless otherwise defined or the context otherwise requires, the following expressions have the following meanings:

“Articles of Association”	the articles of association of the Company as amended, modified or otherwise supplemented from time to time
“Board”	the board of Directors
“Company”	LongBio Pharma (Suzhou) Co., Ltd. (天辰生物醫藥(蘇州)股份有限公司), a joint stock company incorporated in the People’s Republic of China with limited liability, whose H Shares are listed on the Stock Exchange (Stock Code: 1779)
“Director(s)”	the director(s) of the Company
“EGM”	the extraordinary general meeting of the Company to be held at 4:00 p.m. on Thursday, September 10, 2026 at Room 302, Building 88, No. 887 Zuchongzhi Road, Zhangjiang High-Tech Park, Pudong New District, Shanghai, PRC, or any adjournment thereof
“Group”	the Company and its subsidiaries
“H Share(s)”	overseas listed foreign shares issued by the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong dollars
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Latest Practicable Date”	August 20, 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange (as amended from time to time)
“PRC”	The People’s Republic of China
“RMB”	Renminbi, the lawful currency of the PRC

DEFINITIONS

“Share(s)”	the Unlisted Share(s) and the H Share(s) of the Company
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Unlisted Share(s)”	ordinary share(s) issued by the Company, which is/are not listed on any stock exchange, with a nominal value of RMB1.00 each

LETTER FROM THE BOARD

longbio

天 辰 生 物

LongBio Pharma (Suzhou) Co., Ltd.
天辰生物醫藥（蘇州）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1779)

Executive Directors:

Dr. Liu Heng (劉恒博士) (*Chairman*)
Dr. Sun Bill Nai-chau (孫乃超博士)
Mr. Xie Ming (謝鳴先生)

Non-executive Directors:

Mr. Lin Jian (蔺劍先生)
Ms. Gu Qin (顧勤女士)
Dr. Xue Di (薛滌博士)
Dr. Chen Kan (陳侃博士)

Independent Non-executive Directors:

Mr. Siu Paul Yu Hay (蕭耀熙先生)
Mr. Ruan Tim (阮添士先生)
Mr. Yang Chun (楊春先生)
Mr. Zhou Guofang (周國防先生)

Registered Office:

5th Floor, Building F, Area A
No. 128 Yinhe Road, Dongnan Subdistrict
Changshu City
Suzhou City
Jiangsu Province
PRC

Principal Place of Business in Hong Kong:

40/F, Dah Sing Financial Centre
248 Queen's Road East
Wanchai
Hong Kong

August 21, 2026

To the Shareholders

Dear Sir/Madam,

**PROPOSED APPOINTMENT OF A NON-EXECUTIVE DIRECTOR
AND
NOTICE OF EXTRAORDINARY GENERAL MEETING**

I. INTRODUCTION

The purpose of this circular is to provide you with the notice of the EGM and further information on the proposed appointment of non-executive Director, so as to enable you to make an informed decision on voting in respect of the resolution to be proposed at the EGM.

LETTER FROM THE BOARD

II. PROPOSED APPOINTMENT OF A NON-EXECUTIVE DIRECTOR

Reference is made to the announcement of the Company dated August 21, 2026 in relation to, among others, the proposed change of non-executive Director.

The Board, having considered the recommendation of the nomination committee of the Board, has resolved to propose the appointment of Mr. Xue Kailu (薛凱路) (“**Mr. Xue**”) as a non-executive Director. The proposed appointment of Mr. Xue is subject to approval by the Shareholders by way of ordinary resolution at an extraordinary general meeting of the Company (the “**EGM**”) to be convened. The term of office of Mr. Xue shall commence from the date of approval at the EGM and expire upon the conclusion of the term of the current session of the Board.

The biographical details of Mr. Xue are set out below:

Mr. Xue Kailu (薛凱路), aged 39, has over 17 years of experience in biological analysis. From June 2009 to October 2016, Mr. Xue worked as a project manager of WXAT Shanghai (上海藥明康德新藥開發有限公司) and WuXi AppTec (Wuhan) Co., Ltd. (武漢藥明康德新藥開發有限公司), both of which are subsidiaries of WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司), a company listed on the Stock Exchange (stock code: 2359) and Shanghai Stock Exchange (stock code: 603259). From November 2016 to April 2017, he worked at Caresun Pharmaceutical Co., Ltd. (康誠科瑞醫藥研發(武漢)有限公司) (“**Caresun Pharmaceutical**”) as the director of analytics. From May 2017 to November 2017, Mr. Xue was the director of analytics of Xi'an United Nations Safety Evaluation Center (西安國聯安全評價中心). From December 2017 to July 2018, he was the project manager of Shanghai Xihua Scientific Co., Ltd. (上海熙華檢測技術服務有限公司). Since August 2018, Mr. Xue has been the deputy general manager of Caresun Pharmaceutical. Mr. Xue obtained a bachelor's degree majoring in applied chemistry from Nanjing Agricultural University in June 2009.

Subject to the Shareholders approving the proposed appointment of Mr. Xue as a non-executive Director at the EGM, the Company will enter into a letter of appointment with Mr. Xue for the term of office commencing from the date of which his appointment is approved at the EGM and continue until the expiry of the term of the current session of the Board, and he will be eligible for re-election upon the expiry of his term of office. The proposed director's fee for Mr. Xue shall be RMB250,000 per annum (tax inclusive), which has been recommended by the remuneration committee of the Board and approved by the Directors with reference to, inter alia, his qualifications and experience, duties and responsibilities with the Company, and the prevailing market conditions.

Save as disclosed, Mr. Xue has confirmed that (i) he does not hold any position with the Company or any other member of the Group; (ii) he has not held any directorship in any public company listed on any securities market in Hong Kong or overseas during the past three years; (iii) he does not have any relationship with any Director, member of the senior management, substantial shareholder or controlling shareholder of the Company; (iv) he does not have any interest or short position in any shares, underlying shares or debentures of the Company or any

LETTER FROM THE BOARD

of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) there is no other information relating to his proposed appointment that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules nor are there any other matters that need to be brought to the attention of the Shareholders.

III. NOTICE OF EGM

The EGM will be convened and held at 4:00 p.m. on Thursday, September 10, 2026 at Room 302, Building 88, No. 887 Zuchongzhi Road, Zhangjiang High-Tech Park, Pudong New District, Shanghai, PRC. The notice convening the EGM is set out on pages 7 to 8 of this circular and published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.longbio.com).

IV. CLOSURE OF REGISTER OF MEMBERS

The register of members of the Company will be closed from Monday, September 7, 2026 to Thursday, September 10, 2026, both days inclusive, for the purpose of ascertaining the entitlement of Shareholders to attend and vote at the EGM. Shareholders whose names appear on the register of members of the Company on Thursday, September 10, 2026 will be entitled to attend and vote at the EGM.

In order to qualify for attending and voting at the EGM, all instruments of transfer accompanied by the relevant share certificates and transfer forms must be lodged with the Company's Hong Kong H share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, by no later than 4:30 p.m. on Friday, September 4, 2026.

V. PROXY ARRANGEMENTS

The form of proxy for the EGM is enclosed and published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.longbio.com).

If you intend to appoint a proxy to attend the EGM, you are required to complete and return the accompanying form of proxy in accordance with the instructions printed thereon. The form of proxy must be deposited at the Company's Hong Kong H share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 24 hours before the scheduled time of the EGM or any adjournment thereof (i.e. before 4:00 p.m. on Wednesday, September 9, 2026). Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM or any other adjourned meeting should you so wish.

If you attend and vote in person at the EGM, the authority of your proxy will be deemed to be revoked.

LETTER FROM THE BOARD

VI. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules and the Articles of Association, any vote of the Shareholders at the EGM shall be taken by poll except where the chairman of the meeting may, in good faith and in accordance with the Listing Rules, allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands. The poll results will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.longbio.com) after the EGM in accordance with the Listing Rules.

To the best of the Directors' knowledge, information and belief, none of the Shareholders are required to abstain from voting at the EGM.

VII. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

VIII. RECOMMENDATION

The Board considers that the resolution proposed at the EGM is in the best interests of the Company and the Shareholders as a whole. Accordingly, the Board recommends the Shareholders to vote in favor of the proposed resolution.

By order of the Board

LongBio Pharma (Suzhou) Co., Ltd.

Dr. Liu Heng

Chairman of the Board and Executive Director

NOTICE OF EXTRAORDINARY GENERAL MEETING

longbio

天 辰 生 物

LongBio Pharma (Suzhou) Co., Ltd.
天辰生物醫藥（蘇州）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1779)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the extraordinary general meeting (the “**EGM**”) of LongBio Pharma (Suzhou) Co., Ltd. (the “**Company**”) will be convened and held at Room 302, Building 88, No. 887 Zuchongzhi Road, Zhangjiang High-Tech Park, Pudong New District, Shanghai, PRC, on Thursday, September 10, 2026 at 4:00 p.m. to consider and, if thought fit, to approve the following matter. Unless the context otherwise requires, the terms and expressions used herein shall have same meanings as those defined in the circular of the Company dated August 21, 2026 (the “**Circular**”).

ORDINARY RESOLUTION

1. To consider and approve the proposed appointment and remuneration of Mr. Xue Kailu as a non-executive Director.

By order of the Board

LongBio Pharma (Suzhou) Co., Ltd.

Dr. Liu Heng

Chairman of the Board and Executive Director

Hong Kong, August 21, 2026

As of the date of this notice, the Board comprises (i) Dr. LIU Heng, Dr. SUN Bill Nai-chau and Mr. XIE Ming as executive Directors; (ii) Mr. LIN Jian, Ms. GU Qin, Dr. XUE Di and Dr. CHEN Kan as non-executive Directors; and (iii) Mr. SIU Paul Yu Hay, Mr. RUAN Tim, Mr. YANG Chun and Mr. ZHOU Guofang as independent non-executive Directors.

NOTICE OF EXTRAORDINARY GENERAL MEETING

Notes:

1. All resolutions at the EGM will be voted on by way of a poll in accordance with the Listing Rules (except for the Chairman's decision to vote by a show of hands for resolutions relating to administrative matters). The poll results will be published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.longbio.com) after the EGM in accordance with the Listing Rules.
2. For the purpose of ascertaining the right to attend and vote at the EGM, the register of members of the Company will be closed from Monday, September 7, 2026 to Thursday, September 10, 2026, both days inclusive, during which period no transfer of shares will be registered. In order to qualify for attending and voting at the EGM, unregistered holders of the Company's H Shares must ensure that all instruments of transfer, accompanied by the relevant share certificates, must be lodged with the Company's share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not later than 4:30 p.m. on Friday, September 4, 2026. Shareholders whose names appear on the register of members of the Company on Thursday, September 10, 2026 will be entitled to attend and vote at the EGM.
3. Any shareholder of the Company entitled to attend and vote at the EGM is entitled to appoint more than one proxy to attend and vote in his/her stead provided that each proxy so appointed represents the respective number of shares held by the shareholder as specified in the relevant form of proxy. A proxy need not be a shareholder of the Company.
4. Individual Shareholders who wish to attend the EGM in person should present their identity cards or other valid identification or proof of identity and shareholding account cards. Proxies of individual Shareholders should present their valid identification documents and forms of proxy. A corporate Shareholder shall be represented at the meeting by its legally authorized person or by a proxy appointed by the legally authorized person. The legally authorized person intending to attend the meeting should produce his/her identity card or other valid proof of legally authorized person status. If appointed to attend the meeting, the proxy shall present his/her identity card and an authorization duly signed by the legally authorized person of the corporate Shareholder.
5. The instrument appointing a proxy shall be signed by the Shareholder or by his/her attorney duly authorized in writing. In the case of a Shareholder which is a corporation, the instrument appointing a proxy shall be under its common seal or shall be signed by its director or by its duly authorized representative in writing. In the case of an instrument of proxy purporting to be signed by a person authorized by the appointor, the power of attorney or other authority under which it is signed shall be notarially certified and shall be delivered at the same time as the instrument of proxy.

To be valid, the form of proxy together with a notarially certified copy of the power of attorney or other authority must be deposited at the Company's H share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not later than 24 hours prior to the time appointed for the holding of the EGM or any adjournment thereof (i.e. before 4:00 p.m. on Wednesday, September 9, 2026).

Where there are joint registered holders of any Share, any one of such joint registered holders may vote at the EGM, either personally or by proxy, in respect of such share as if he were solely entitled thereto, but if more than one of such joint registered holders be present at the EGM personally or by proxy, that one of the said persons so present whose name stands first on the register of members of the Company in respect of such share, either personally or by proxy, shall alone be accepted as representing the joint holder.

Completion and return of the form of proxy and the instrument of proxy will not preclude you from attending and voting in person at the EGM or any adjournment thereof should you so wish. In such event, the instrument of proxy shall be deemed to be revoked.

6. Shareholders attending the EGM are responsible for their own travelling and accommodation expenses.